Company news
Jiangsu Kanion Pharmaceutical Co. Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
November 2, 2026
(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Report for Q3 2026
October 29, 2026
(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Key Operating Data for the First Three Quarters of 2026
October 29, 2026
(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Receipt of the Clinical Trial Approval Notice for Shiwei Anchang Granules
October 22, 2026
(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Departure of Senior Executive
October 16, 2026
(600557)"Jiangsu Kanion Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
October 9, 2026
Semi-annual Report for 2026
August 27, 2026
Announcement on Receipt of the Clinical Trial Approval Notice for Qihuang Zhengqi Granules
July 21, 2026
Announcement on Initially Repurchasing Shares through Call Auction
July 16, 2026
Announcement on Inclusion of Certain Pharmaceutical Products of the Company in the National Essential Medicines List
July 9, 2026
Announcement on Progress in Repurchasing Shares through Call Auction
July 3, 2026
Announcement on Cancellation of Repurchased Shares and Notification to Creditors
June 26, 2026
Announcement on Shareholding of Top 10 Shareholders and Top 10 Holders of Shares Without Sales Limit
June 22, 2026
Notice on Convening the 2025 Annual General Meeting
June 5, 2026
Report for Q1 2026
April 29, 2026
Announcement on Convening Performance Briefing for 2025 and Q1 2026
April 28, 2026
Announcement on Renewing Engagement of Accounting Firm
April 22, 2026
Announcement on Receiving the Clinical Trial Approval Notice for Qingshen Tongluo Granules
April 19, 2026
Announcement on Appointment of Deputy General Manager
March 30, 2026
Announcement on Receiving the Clinical Trial Approval Notice for Heihuang Chizhu Granules
February 25, 2026
Announcement on the Receipt of the Clinical Trial Approval Notice for Yunpi Huatan Tongqiao Granules
January 26, 2026
Announcement on the Receipt of the Clinical Trial Approval Notice for Plantago Seed Tablets
January 20, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
December 29, 2025
Announcement on Obtaining the Drug Registration Certificate for Xiebai San Granules
December 12, 2025
Announcement on Cancelling the Board of Supervisors and Amending the Articles of Association and Some Governance Systems
December 11, 2025
Announcement on Shareholding Increase Result of Some Directors and Senior Management Members
December 9, 2025
Announcement on the Inclusion of the Company’s Partial Drugs in the National Medical Insurance Catalog
December 8, 2025
江苏康缘药业股份有限公司关于实际控制人、董事增持公司股份的公告
November 18, 2025
Announcement on Shareholding Increase by Persons Acting in Concert of Actual Controllers
November 12, 2025
Announcement on Voluntary Shareholding Increase Plan by Certain Directors and Senior Management Members
November 7, 2025
Report for Q3 2025
October 30, 2025
Announcement on Wholly-owned Subsidiary's Drug Additional Indication Obtaining Clinical Trial Approval Notice
October 29, 2025
Announcement on Pledge of Some Shares Held by Shareholders with Over 5% Shares
September 26, 2025
2025 Semi-annual Report
August 27, 2025
Announcement on the Receipt of the Clinical Trial Approval Notice for Jinzhen Oral Liquid with Increased Indications
August 22, 2025
Announcement on the Receipt of the Clinical Trial Approval Notice for Jianpi Shugan Guben Granules
August 18, 2025
Announcement on Obtaining Drug Registration Certificate for Shenpu Granules
August 3, 2025
Announcement on the Receipt of the Clinical Trial Approval Notice for KYS2301 Gel
July 3, 2025
Announcement on Outgoing of Chairman
June 20, 2025
Announcement on Completing Industrial and Commercial Change Registration and Obtaining Renewed Business License
June 10, 2025
Announcement on Passive Increase in Shareholding Ratio of Controlling Shareholder Due to Repurchase and Cancellation of Restricted Stocks by the Company Touching an Integer Multiple of 1%
May 30, 2025
Announcement on Implementing Repurchase and Cancellation of All Remaining Restricted Stocks under the 2022 Annual Restricted Stocks Incentive Plan
May 26, 2025
Announcement on Convening the 2024 Annual and Q1 2025 Performance Briefing
May 20, 2025
Announcement on Main Operating Data for Q1 2025
April 29, 2025
Announcement Obtaining Drug Registration Certificate for Gypsum Decoction Granules
April 27, 2025
Announcement on Resolutions of the 2024 Annual General Meeting
April 24, 2025
Announcement on Resolutions of the 16th Meeting of the 8th Board of Directors
April 2, 2025
Announcement on Receiving the Notice of Approval for Clinical Trials of Lianshen Gengnian Granules
March 27, 2025
Announcement on Receiving the Notice of Approval for Clinical Trials of Guben Xiaozhen Granules
March 4, 2025
Announcement on the Completion of Shareholding Increase Plan by Persons Acting in Concert with Controlling Shareholders and Results of the Increase
February 26, 2025